ACM
NGNE icon

ADAR1 Capital Management’s Neurogene NGNE Stock Holding History

ADAR1 Capital Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-30,633
Closed -$631K – 328
2025
Q4 		$631K Hold
30,633
– – 0.05% 174
2025
Q3 		$531K Buy
30,633
+1,008
+3% +$20.2K 0.05% 132
2025
Q2 		$443K Buy
29,625
+1,700
+6% +$26.7K 0.07% 123
2025
Q1 		$327K Buy
+27,925
New +$485K 0.06% 124
2024
Q4 		– Sell
-553
Closed -$23.2K – 275
2024
Q3 		$23.2K Sell
553
-700
-56% -$27.1K ﹤0.01% 241
2024
Q2 		$45.6K Buy
1,253
+592
+90% +$20.9K 0.01% 190
2024
Q1 		$33.6K Sell
661
-4,744
-88% -$158K 0.01% 202
2023
Q4 		$105K Buy
+5,405
New +$77.4K 0.04% 94

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

ADAR1 Capital Management's NGNE Position: Q1 2026 in Review

ADAR1 Capital Management sold out of Neurogene (NGNE) in Q1 2026, closing a stake of 30,633 shares — an estimated $631K sold.

ADAR1 Capital Management first reported a position in NGNE in Q4 2023 and held it in 8 quarters. The position peaked at $631K in Q4 2025. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • ADAR1 Capital Management reported no remaining Neurogene position as of Q1 2026 after selling out during the quarter.
  • ADAR1 Capital Management sold 30,633 Neurogene shares in Q1 2026, an estimated $631K.
  • ADAR1 Capital Management first reported a position in Neurogene in Q4 2023 and held it in 8 quarters.
  • ADAR1 Capital Management's Neurogene position peaked at $631K in Q4 2025.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.